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Abstract
Immuno-enzymosomes have been proposed for the targeting of enzymes to cancer cells to achieve site specific activation of
anticancer prodrugs. Previously, we reported that the enzyme L-glucuronidase (GUS), capable of activating anthracycline-
glucuronide prodrugs, can be coupled to the surface of inmunoliposomes directed against human ovarian cancer cells
(OVCAR-3). This study aimed at the design of an immuno-enzymosome formulation with maximum enzyme targeting
capability. By purification of the commercially available enzyme L-glucuronidase (GUS), a 2-fold increase in the enzyme
specific activity and a 4-fold increase in the enzymatic activity of immuno-enzymosomes was achieved. As a result, upon
incubation with human ovarian cancer cells (OVCAR-3), cell-associated enzymatic activity increased correspondingly. The
optimized immuno-enzymosomes were shown to bind to the target cells in a specific fashion. Above a GUS/FabP molar ratio
of 0.5, impairment of the target cell binding ability of the immuno-enzymosomes was observed. This was likely due to a steric
hindrance effect mediated by the presence of large amounts of bulky GUS molecules on the liposome surface. Nevertheless,
increasing the GUS density on the surface of the immuno-enzymosomes to levels by far exceeding the GUS/FabP molar ratio
of 0.5, yielded a considerably improved enzyme targeting capability. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
The e⁄cacy of conventional anticancer drugs used
in chemotherapy is limited by the lack of selectivity
for cancer cells. In principle, the conjugation of cell
speci¢c antibodies to liposomes (immunoliposomes)
containing chemotherapeutic agents provides the
possibility for selective drug delivery and cell type
speci¢c cytotoxicity [1^4]. Another drug targeting
strategy in cancer chemotherapy is the use of anti-
bodies to carry enzymes to tumor cells. This concept
is referred to as antibody-directed enzyme prodrug
therapy (ADEPT) [5^8]. Usually it involves the ad-
ministration of an antibody-enzyme conjugate, fol-
lowed by the injection of a relatively non-toxic pro-
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drug after binding of the conjugate to the tumor cells
and clearance from blood and other tissues. In close
proximity of the tumor cell, the prodrug is converted
into the parent cytotoxic agent by the targeted en-
zyme, which may result in selective tumor cell kill.
Previously, we have presented a modi¢cation of this
approach based on the use of immunoliposomes. In
this case both antibody and enzyme are covalently
coupled to the surface of liposomes, a system here-
after referred to as immuno-enzymosomes [9^11].
The enzyme chosen for our immuno-enzymosome
system was L-glucuronidase (GUS), able to activate
glucuronidated drugs. GUS has the advantage over
other enzymes commonly used in ADEPT, such as
alkaline phosphatase [12,13] that it is not present in
blood at detectable levels, but localized only intra-
cellularly [14]. Thus, untimely activation of prodrug
is limited as hydrophilic glucuronide prodrugs do not
readily di¡use into cells [15]. Another advantage of
using GUS is that it is possible to use the human
homologue. This may potentially reduce the immu-
nogenicity problem induced by GUS attached to the
liposomes. The selected targeting device, the mono-
clonal antibody 323/A3 (mouse IgG 1) [16], reacts
with a pancarcinoma antigen epithelial transmem-
brane glycoprotein with a molecular mass of 40
kDa (referred to as EGP40 or epithelial cell adhesion
molecule, Ep-CAM) [17]. This antigen is highly ex-
pressed on the surface of most carcinomas, including
breast, ovary, lung and colon tumors. We used FabP
fragments of the antibody for two reasons. Firstly,
the method used for coupling the FabP fragments to
the liposomes (covalent linkage to the MPB-PE an-
chor present in the outer lipid bilayers of preformed
liposomes) ensures an adequate orientation of the
FabP fragments on the liposomes, with the antigen
binding sites directed outward and fully accessible to
antigen binding. Secondly, the removal of the Fc
part of the IgG molecule can be of great importance
for in vivo use of immuno-enzymosomes. In this way
the Fc receptor of macrophages is not activated and
elimination of the liposome, by the mononuclear
phagocyte system (MPS), might be reduced and
slowed down [18].
A theoretical advantage of the so-called ‘immuno-
enzymosomes’ over antibody-enzyme conjugates is
that many more than one enzyme molecule can be
included in one targeted carrier unit. Under the
proper conditions, this may create the opportunity
to increase the enzyme density at the tumor cell sur-
face, which accordingly may lead to a more e⁄cient
conversion of the prodrug into the active cytotoxic
parent compound. Earlier we have successfully pre-
pared immuno-enzymosomes able to speci¢cally bind
in vitro to human ovarian carcinoma cells (OVCAR-
3) and subsequently convert the prodrugs epirubicin-
glucuronide [9] and daunorubicin-glucuronide [10]
into their toxic parent compounds. The aim of this
study was to design an immuno-enzymosome formu-
lation with maximized enzyme activity. Since we con-
sidered it likely that steric hindrance by the bulky
GUS molecule would negatively a¡ect the interaction
of the liposomal FabP fragments with the cells, we
varied, in addition, the enzyme density on the immu-
noliposomes and investigated what in£uence this had
on the amount of enzyme that can be delivered to the
target cells.
2. Materials and methods
2.1. Chemicals
Fetal calf serum (FCS) was obtained from Bock-
nek Laboratories (Canada). DMEM was obtained by
Flow Laboratories (Irving, UK). The mouse mono-
clonal antibody 323/A3 (IgG type) was donated by
Centocor Europe BV (Leiden, The Netherlands). L-
Glucuronidase (GUS) from Escherichia coli K12 and
p-nitrophenyl-L-D-glucuronide were purchased from
Boehringer (Mannheim, Germany). Cell culture
£asks were from Falcon (Micronic BV, Lelystad,
The Netherlands). Succinimidyl 4-(p-maleimido-
phenyl)butyrate (SMPB) was obtained from Pierce
(Oud-Beijerland, The Netherlands). Egg phosphati-
dyl choline (EPC), egg-phosphatidylglycerol (EPG)
were donated by Lipoid (Ludwigshafen, Germany).
Phosphatidyl ethanolamine (PE) was obtained from
Nut¢eld Nurseries Lipid Products (Nut¢eld, UK).
Cholesterol (CHOL), N-succinimidyl S-acetylthio-
acetate (SATA), bovine serum albumin (BSA), di-
thiothreitol (DTT), and FITC-conjugated goat anti-
mouse IgG was obtained from Sigma Chemical Co.
(St. Louis, MO, USA). 4-Methylumbelliferyl-L-D-glu-
curonide tryhydrate was from Fluka (Buchs, Switzer-
land). All other reagents were of analytical grade.
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2.2. Puri¢cation of GUS
Commercially available GUS from E. coli K12
(Boehringer, Mannheim, Germany) was puri¢ed by
gel ¢ltration chromatography. GUS was applied
onto a Sephadex G-150 column and eluted with
phosphate bu¡ered saline (PBS containing 1 mM
EDTA, pH 7.2). The presence of protein in the col-
lected fractions was checked by reaction with Coo-
massie protein reagent (absorbance was measured at
595 nm). Fractions containing protein were subse-
quently checked for enzyme activity. Diluted samples
(10 Wl) were incubated with p-nitrophenyl-L-D-glu-
curonide (10 mM in PBS containing 0.1% BSA)
(190 Wl) for 30 min at 37‡C. The reaction was termi-
nated by the addition of 50 Wl of 1 M glycine (pH
10.6) and absorbance was read at 405 nm. Protein-
rich fractions were pooled on the basis of the absorb-
ance values. This enzyme solution was concentrated
by means of a Macrosept concentrator (30K) (Cen-
triprep, Amicon).
2.3. Enzyme thiolation
Thiolation of GUS was carried out by reaction
with N-succinimidyl S-acetylthioacetate (SATA) as
described before [10]. Puri¢ed GUS (Pur-GUS) was
used directly. Unpuri¢ed commercial GUS (GUS)
was ¢rst subjected to gel ¢ltration chromatography
on a Sephadex G-25M column (PD-10, Pharmacia,
Woerden, The Netherlands) in order to exchange the
medium (50% glycerol) for phosphate bu¡ered saline
(PBS). Either puri¢ed or non-puri¢ed GUS were in-
cubated with SATA (dissolved in dimethylformamide
(DMF)) at a molar ratio of 1:8 for 20 min at room
temperature in a nitrogen atmosphere [19]. SATA,
DMF and PBS were then exchanged for acetate bu¡-
er pH 6.5 using gel ¢ltration chromatography (Se-
phadex G-25M). Modi¢ed GUS (GUS-ATA) was
stable for at least one month at 4‡C. For covalent
attachment to freshly prepared liposomes, the new
SH groups introduced to GUS were deprotected by
addition of hydroxylamine (see below).
2.4. Preparation of FabP fragments
The mouse monoclonal antibody 323/A3 (IgG
1 type) recognizes an Mr 43 kDa membrane glycopro-
tein which is expressed on a variety of carcinomas
[9,16]. F(abP)2 fragments were produced by pepsin
digestion. The pH of the IgG solution was adjusted
to 4.5 immediately before digestion. Pepsin attached
to 4% cross-linked beaded agarose was added at a
ratio of 100 U per mg of IgG. The mixture was
incubated under constant rotation at 37‡C overnight.
After adjusting the pH to 7.4 using 1.0 and 0.1 M
NaOH solution, the mixture was centrifuged at
4000 rpm for 10 min to remove the pepsin-coated
beads. The protein solution was ¢ltered through a
0.2 Wm ¢lter, applied onto a Protein A-Sepharose
CL-6B column (Pharmacia AB, Uppsala, Sweden)
and eluted with 100 mM acetate bu¡er pH 7.4.
Eluted fractions containing F(abP)2 fragments were
collected and concentrated by means of a Macrosept
concentrator (30K). Purity of F(abP)2 was assessed
by sodium dodecylsulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) under non-reducing condi-
tions and by gel permeation chromatography using
a BioSep-SEC-S2000 column (Phenomenex, CA,
USA). Degassed phosphate bu¡ered saline (PBS)
was used as the mobile phase. Immediately before
incubation with liposomes, FabP fragments were pre-
pared by incubation of F(abP)2 with 20 mM DTT in
acetate bu¡er at pH 5.5 (100 mM sodium acetate,
63 mM NaCl, 1 mM EDTA) for at least 90 min at
room temperature [20]. DTT was removed by apply-
ing the incubation mixture onto a Sephadex G-25M
column (PD-10) and subsequent elution with acetate
bu¡er pH 6.5 (100 mM NaAC, 40 mM NaCl, 1 mM
EDTA, deoxygenated and £ushed with nitrogen be-
fore use). FabP fragments appearing in the void vol-
ume were used immediately for covalent attachment
to freshly prepared liposomes (see below).
2.5. Preparation of immunoliposomes, enzymosomes
and immuno-enzymosomes
N-[4-(p-maleimidophenyl)butyryl]phosphatidyletha-
nolamine (MPB-PE) was synthesized from SMPB
and PE, puri¢ed and analyzed as described before
[20]. MPB-PE was incorporated into the liposome
bilayers to allow covalent coupling of thiolated
GUS and FabP fragments to the liposome surface.
Liposomes composed of EPC:EPG:CHOL at a mo-
lar ratio of 10:3:4 with 2.5 mol % MPB-PE were
prepared by hydration of the lipid ¢lm in HEPES
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NaCl bu¡er (20 mM HEPES, 149 mM NaCl, 1 mM
EDTA, pH 7.4). Occasionally, when immunolipo-
somes were prepared the lipid ¢lm was hydrated
with a 40 mM calcein solution. The resulting lipo-
some dispersion was extruded through polycarbonate
membrane ¢lters with 0.2 Wm pore size under nitro-
gen pressure, yielding a mean size of about 0.2 Wm.
After extrusion the HEPES/NaCl bu¡er outside the
liposomes was replaced by acetate bu¡er pH 6.5 us-
ing ultracentrifugation (200 000Ug, 45 min). Freshly
prepared liposomes were mixed with either GUS-
ATA or Pur-GUS-ATA and freshly prepared FabP
fragments. Concentrations during incubation were 5^
10 Wmol TL/ml, 1^2.5 mg/ml of thiolated GUS and
0.1^0.75 mg FabP/ml). Freshly prepared hydroxyl-
amine HCl (0.5 M hydroxylamine HCl, 0.5 M
HEPES, 25 mM EDTA, pH 6.5) was added to the
incubation mixture for deprotection of the (Pur)-
GUS-ATA SH groups (100 Wl hydroxylamine solu-
tion per ml of incubation mixture). The coupling
reaction was carried out overnight at 4‡C under con-
stant rotation in a nitrogen atmosphere. Finally, the
immunoliposomes were separated from unconjugated
enzyme and FabP by ultracentrifugation (200 000Ug,
45 min). The pellet was resuspended and washed
twice with HEPES/NaCl bu¡er. Liposomes to which
only (Pur)-GUS is coupled (no FabP) are further re-
ferred to as enzymosomes. Liposomes to which both
(Pur)-GUS and FabP are coupled are referred to as
immuno-enzymosomes. Liposome dispersions were
stored at 4‡C.
2.6. Liposome characterization
Lipid phosphate was determined by the colorimet-
ric method of Rouser [21]. The enzymatic activity
was measured with p-nitrophenyl-L-D-glucuronide
as described above. The amount of protein coupled
to the liposomes was determined by the method of
Wessel and Flu«gge [22], with bovine serum albumin
as standard. The total amount of monoclonal anti-
body and/or enzyme coupled to the liposomes was
expressed as Wg protein/Wmol total lipid (TL). The
amount of enzyme coupled to immuno-enzymosomes
was estimated by comparison of the enzyme density
and enzymatic activity of enzymosomes (to which
only (Pur)-GUS is coupled) with the protein density
and enzymatic activity of immuno-enzymosomes.
Mean particle size was determined by dynamic light
scattering with a Malvern 4700 system using a 25
mW helium^neon laser. As a measure of the particle
size distribution of the dispersion the system reports
a polydispersity index. This index ranges from 0.0 for
a monodisperse up to 1.0 for a polydisperse disper-
sion.
2.7. Cell binding assay
The human ovarian cancer cell line NIH:OVCAR-
3 [23] was maintained in Dulbecco’s modi¢ed Eagle’s
medium supplemented with 10% FCS, L-glutamine
(2 mM), penicillin (100 units/ml), streptomycin (100
Wg/ml) and amphotericin B (0.25 Wg/ml). The ovarian
carcinoma cell line A2780, which lacks the antigen
for 323/A3, was cultured under similar conditions
and provided control cells. Adherent cells (OV-
CAR-3 or A2780) were detached with 0.05% tryp-
sine, 0.02% EDTA in phosphate bu¡ered saline
(PBS, pH 7.4) for 5 min at 37‡C, and were washed
once with cold PBS. Cells were treated in triplicate
with calcein-containing immunoliposomes, immuno-
enzymosomes or enzymosomes for 90 min at 4‡C
with vortexing at 30 min intervals. Unless otherwise
stated, the lipid concentration and cell concentration
in the incubation medium were 1 Wmol TL/ml and
106 cells/ml, respectively. Unbound liposomes were
separated from the cells by centrifugation (300Ug,
3 min). The cell pellet was washed twice with PBS
containing 1% BSA. The degree of cell binding of
immunoliposomes was assessed by £uorescence of
pellets and supernatants (excitation-emission wave-
length of 490^519 nm) in a Perkin Elmer LS-50 (Bea-
cons¢eld, Buckinghamshire, UK) spectro£uorimeter.
Cell binding of enzymosomes and immuno-enzymo-
somes was determined by measuring the enzymatic
activity in the redispersed cell pellet by reaction with
the substrate p-nitrophenyl-L-D-glucuronide as de-
scribed above. For direct comparison of the binding
properties of immunoliposomes and immuno-enzy-
mosomes £ow cytometry was used. Suspensions of
OVCAR-3 cells in PBS containing 1% BSA were in-
cubated with varying amounts of immunoliposomes
and immuno-enzymosomes at 4‡C for 90 min. After
incubation, cells were washed twice with PBS con-
taining 1% BSA by centrifugation (300Ug, 3 min)
and incubated at 4‡C for 30 min with FITC-conju-
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gated goat anti-(mouse IgG) (FabP speci¢c) at a di-
lution 1:200. After washing twice with ice-cold PBS,
cell £uorescence was analyzed by a £ow cytometer
FACScan (Becton and Dickinson Immunocytometry
Systems, Mountain View, CA, USA), with excitation
at 488 nm and emission at 515^545 nm. The £uores-
cence intensity of 10 000 viable cells was recorded.
Mean £uorescence intensity was computed.
2.8. Enzyme targeting capability of
immuno-enzymosomes
Varying amounts of immuno-enzymosomes were
incubated with OVCAR-3 cells (106 cells/ml) for 90
min at 4‡C. Unbound liposomes were separated from
the cells by centrifugation (300Ug, 3 min). The cell
pellet was washed twice with PBS containing 0.1%
BSA. The cell-associated enzymatic activity was de-
termined by incubation with 100 Wl of 5 mM 4-meth-
ylumbelliferyl-L-D-glucuronide trihydrate for 1 h at
37‡C. The reaction was terminated by addition of
1 ml 0.1 M glycine (pH 10.6). Fluorescence was
measured at excitation-emission wavelengths of
370^460 nm in a Perkin Elmer 3000 (Norwalk, CT,
USA) spectro£uorimeter.
3. Results
3.1. E¡ect of puri¢cation of commercially available
L-glucuronidase on the enzymatic activity of
immuno-enzymosomes
Puri¢cation of a commercial GUS preparation led
to a 2-fold increase in speci¢c activity (Table 1). As
thiolation of GUS is necessary for e⁄cient coupling
to the liposomes [9,10], it was important to check
whether the enzymatic activity was a¡ected by reac-
tion with the thiolating agent N-succinimidyl S-ace-
tylthioacetate (SATA). Table 1 shows that puri¢ed
GUS did not lose activity by reaction with SATA
(Pur-GUS-ATA).
Immuno-enzymosomes and enzymosomes bearing
unpuri¢ed or puri¢ed GUS were prepared by cou-
pling the proteins (FabP and/or GUS) to liposomes
containing the anchor molecule MPB-PE. Table 2
summarizes the characteristics of these liposome
preparations. The size distribution of all preparations
remained stable for at least 1 month of storage.
Clearly, when puri¢ed enzyme was used the degree
of GUS coupling to the liposomes was about 2-fold
enhanced. As a result of the 2-fold increase in speci¢c
enzymatic activity upon puri¢cation (Table 1), and
the 2-fold increase in the degree of GUS coupling
(Table 2), the enzymatic activity of the liposomes
Table 1
Enzyme activity of commercially available L-glucuronidase be-
fore (GUS) and after (Pur-GUS) puri¢cation and SATA reac-
tion (Pur-GUS-ATA). Each value represents the mean þ S.D.,
n = 5
Enzyme Enzyme activity (U/mg)
GUS 21 þ 3
Pur-GUS 42 þ 13
Pur-GUS-ATA 48 þ 11
Table 2
Characterization of liposome preparations
Liposome
Type
Mean size
(Wm)
GUS coupling ratio
(Wg GUS/Wmol TL)
FabP coupling ratio
(Wg FABP/Wmol TL)
Enzymatic activity
(U/Wmol TL)
Ref-EL 0.28 þ 0.01 26 þ 2 ^ 0.17 þ 0.00
Ref-IEL 0.20 þ 0.00 20 þ 1 21 þ 4 0.12 þ 0.00
Pur-EL 0.25 þ 0.02 49 þ 3 ^ 0.65 þ 0.15
Pur-IEL 0.21 þ 0.02 41 þ 1 14 þ 3 0.48 þ 0.00
Enzymosomes were prepared by incubation of MPB-PE liposomes with puri¢ed (Pur-EL) or unpuri¢ed (Ref-EL) GUS-ATA.
Immuno-enzymosomes were prepared similarly (Pur-IEL and Ref-IEL, respectively), but in this case FabP fragments of the IgG 323/
A3 were included in the incubation medium. Conditions in the incubation medium were 6 Wmol TL/ml, 1 mg/ml of GUS-ATA and
0.5 mg/ml FabP.
Results are expressed as mean values þ S.D.; the number of dispersions per group was at least three.
The coupling ratio (Wg FabP/Wmol TL and Wg GUS/Wmol TL) was determined using a protein determination assay, an enzymatic activ-
ity assay and a phosphate determination assay as described in Section 2.
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was 4-fold when puri¢ed GUS was used. Further-
more, the presence of the antibody had only a slight
e¡ect on the amount of enzyme that could be
coupled to the liposomes. Accordingly, the enzyme
activity bound to target cells after incubation with
immuno-enzymosomes prepared with puri¢ed GUS
(Pur-IEL) was expected to be higher than that ob-
tained after incubation with immuno-enzymosomes
prepared with non-puri¢ed GUS (Ref-IEL). To ver-
ify this, Ref-IEL and Pur-IEL were prepared under
the same conditions and varying amounts of both
preparations were incubated with OVCAR-3 cells.
Fig. 1 shows that immuno-enzymosomes prepared
with puri¢ed L-glucuronidase were able to deliver
up to 5-fold higher enzymatic activity to the cells
than those prepared with non-puri¢ed GUS. For
the remainder of this study, puri¢ed GUS was used
for the preparation of immuno-enzymosomes.
3.2. In vitro targeting of 323/A3 immunoliposomes to
ovarian carcinoma cells
In order to determine the optimal conditions for
further experiments, the e¡ect of lipid concentration
and number of cells present during the incubation on
the degree of cell binding of immunoliposomes was
determined. Fig. 2A shows that, at a constant cell
concentration (106 cells/ml), the relative cell binding
of the 323/A3 immunoliposomes decreased as a func-
tion of the concentration of added liposomes. For
further experiments, a lipid concentration of 1 Wmol
TL/ml was chosen, since above that concentration
the fraction of cell-bound immunoliposomes de-
creased substantially. Fig. 2B shows that the relative
cell binding at 1 Wmol TL/ml can be improved about
3-fold by a 10-fold increase in tumor cell concentra-
tion (from 106 to 107 cells/ml). For practical reasons,
Fig. 1. Enzyme targeting capability of immuno-enzymosomes
prepared with puri¢ed GUS (R) as compared to that of immu-
no-enzymosomes prepared with non-puri¢ed GUS (b). Varying
amounts of both liposome dispersions were incubated with cells
(106 cells/ml) for 90 min at 4‡C. After washing the cells with
PBS containing 0.1% BSA to remove unbound liposomes, the
enzymatic activity was determined. The cell binding is expressed
as the cell-bound enzymatic activity. A typical experiment out
of three performed is shown. Each point represents the
mean þ S.D. of three determinations.
Fig. 2. Target cell binding of immunoliposomes. Calcein-con-
taining (b) 323/A3 immunoliposomes (17 Wg FabP/Wmol TL)
and (8) MPB-PE liposomes were incubated with in vitro grow-
ing OVCAR-3 cells for 90 min at 4‡C. A: Cell concentration
was ¢xed at 106 cells/ml and lipid concentration was variable.
B: Lipid concentration was ¢xed at 1 Wmol/ml and cell concen-
tration was variable. Maximum cell binding was set at 1. A
typical experiment out of three performed is shown. Each point
represents the mean þ S.D. of three determinations.
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however, most of our experiments were performed at
a tumor cell concentration of 106 cells/ml. Fig. 2A
and B also show that the binding of MPB-PE lip-
osomes (lacking the 323/A3 speci¢c monoclonal anti-
body) to OVCAR-3 cells was negligible.
The e¡ect of antibody density on the surface of the
323/A3 immunoliposomes on the degree of cell bind-
ing to OVCAR-3 cells is shown in Fig. 3. An increase
in FabP density on the immunoliposomes resulted in
an increase in cell binding. Under the conditions
used in this study, cell binding was maximal at a
density of around 15 Wg FabP/Wmol TL. A further
increase in FabP density did not result in a further
improved cell binding. When the cells were pre-
treated with an excess of the speci¢c 323/A3 mono-
clonal antibody (IgG), the binding of immunolipo-
somes was completely blocked.
3.3. E¡ect of enzyme density on target cell a⁄nity
and enzyme targeting capability of
immuno-enzymosomes
Fig. 4 shows that immuno-enzymosomes are able
to bind to OVCAR-3 cells in vitro in a speci¢c man-
ner. The degree of cell binding of the immuno-enzy-
mosome preparation used (40 Wg GUS/Wmol TL and
14 Wg FabP/Wmol TL) was comparable to that shown
in Fig. 3 for immunoliposomes (without surface-at-
tached GUS). To demonstrate the speci¢c nature of
the binding, several negative control binding experi-
ments were performed: (1) immuno-enzymosomes
did not bind to A2780 cells which lack the antigen
for 323/A3; (2) the target cell binding of immuno-
enzymosomes was strongly inhibited by pre-incuba-
tion of the cells with the speci¢c monoclonal anti-
body 323/A3; and (3) enzymosomes (lacking the spe-
ci¢c FabP) showed negligible association to OVCAR-
3 cells.
To investigate whether the surface-bound GUS
had a negative e¡ect on cell binding, the cell binding
properties of both immunoliposomes and immuno-
enzymosomes were studied by £ow cytometric anal-
ysis. Fig. 5A shows that the binding a⁄nity of im-
muno-enzymosomes bearing 25 Wg GUS/Wmol TL
and 20 Wg FabP/Wmol TL (GUS/FabP molar ratio
0.2) was comparable to that of the corresponding
immunoliposomes. The same was observed for other
immuno-enzymosome preparations with a GUS/FabP
Fig. 3. E¡ect of the coupled amount of FabP on the cell (OV-
CAR-3) binding properties of calcein-containing 323/A3 immu-
noliposomes (b). Binding of immunoliposomes to OVCAR-3
cells pretreated with an excess of 323/A3 (F), served as a con-
trol. Liposomes (1 Wmol TL/ml) were incubated with cells (106
cells/ml) for 90 min at 4‡C. After washing the cells with PBS
by centrifugation to remove unbound liposomes, £uorescence
was determined. The cell binding is expressed as the absolute
amount of immunoliposomes bound/106 cells. A typical experi-
ment out of three performed is shown. Each point represents
the mean þ S.D. of three determinations.
Fig. 4. In vitro cell binding of immuno-enzymosomes to OV-
CAR-3. (1) Binding of immuno-enzymosomes to OVCAR-3
cells, (2) binding of immuno-enzymosomes to OVCAR-3 cells
pretreated with an excess of 323/A3, (3) binding of immuno-en-
zymosomes to control A2780 cells, and (4) binding of enzymo-
somes to OVCAR-3 cells. Liposomes (1 Wmol TL/ml) were in-
cubated with cells (106 cells/ml) for 90 min at 4‡C. After
washing the cells with PBS containing 1% BSA to remove un-
bound liposomes, the enzymatic activity was determined. The
cell binding is expressed as the absolute amount of (immuno-)-
enzymosomes bound/106 cells. A typical experiment out of three
performed is shown. Each point represents the mean þ S.D. of
three determinations.
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molar ratio lower than 0.5 (data not shown). How-
ever, the cell binding capability of immuno-enzymo-
somes with a higher content of GUS and/or a lower
content of FabP (GUS/FabP molar ratio higher than
0.5) was notably reduced as compared to the corre-
sponding immunoliposomes. The higher the GUS/
FabP ratio, the more pronounced the hindrance on
cell binding capability. Two illustrative examples
with GUS/FabP molar ratios of 0.9 and 3.8 are
shown in Fig. 5B,C, respectively. To ensure that
the observed decrease in cell-associated £uorescence
was due merely to GUS-mediated hindrance of the
binding of immuno-enzymosomes to the cells and
not to problems related to incomplete recognition
of the cell-bound immuno-enzymosomes by the sec-
ondary antibody, the same set of experiments was
performed with liposomes containing the £uorescent
lipid label rhodamine-phosphatidyl ethanolamine. In
all cases, similar results were obtained (data not
shown).
The impact of the steric hindrance e¡ect observed
for immuno-enzymosomes with a GUS/FabP molar
ratio s 0.5 on their enzyme targeting capability
was investigated. Immuno-enzymosomes bearing up
to 80 Wg GUS/Wmol TL and varying contents of FabP
were prepared. In all cases we observed that immu-
no-enzymosomes with the highest enzyme density
were able to target the highest enzymatic activity to
the cells, even in cases when cell binding was strongly
reduced as a result of a strong GUS-mediated steric
hindrance e¡ect. This is illustrated in Fig. 6, which
shows that an immuno-enzymosome with a GUS/
FabP ratio of 3.8, displaying a strongly reduced cell
binding (Fig. 5C) could nonetheless target far more
Fig. 5. Flow cytometric analysis of the binding of immuno-en-
zymosomes (b) to OVCAR-3 cells with varying GUS and FabP
content as compared to immunoliposomes (F) bearing similar
FabP densities. Cells were examined for cell-associated £uores-
cence by £ow cytometry as described in Section 2. The mean
£uorescence value ( þ S.D. n = 3) determined by £ow cytometry
is presented after subtraction of that obtained for cells incu-
bated with only FITC conjugate. A typical experiment out of
three performed is shown. A: GUS coupling ratio: 25 Wg GUS/
Wmol TL (170 molecules of GUS per liposome); FabP coupling
ratio: 20 Wg FabP/Wmol TL (700 molecules of FabP per lipo-
some). GUS/FabP ratio = 0.2. B: GUS coupling ratio: 80 Wg
GUS/Wmol TL (700 molecules of GUS per liposome); FabP
coupling ratio: 15 Wg FabP/Wmol TL (750 molecules of FabP per
liposome). GUS/FabP ratio = 0.9. C: GUS coupling ratio: 70 Wg
GUS/Wmol TL (380 molecules of GUS per liposome); FabP
coupling ratio: 3 Wg FabP/Wmol TL (100 molecules of FabP per
liposome). GUS/FabP ratio = 3.8.
6
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enzymes to the cells than a preparation with a GUS/
FabP ratio of 0.2, displaying fully retained binding
ability (Fig. 5A).
4. Discussion
In this paper we use the targetability of immuno-
liposomes to carry enzymes (immuno-enzymosomes),
capable of activating anticancer prodrugs, to ovarian
cancer cells. Ovarian cancer is one of the most com-
mon fatal gynaecological malignancies. At the time
of diagnosis, the disease is often at a progressed state
and has already spread beyond the ovary within the
peritoneal cavity. The standard treatment of patients
with advanced disease consists of surgical debulking
of the tumor mass followed by combination chemo-
therapy. To improve the poor prognosis, complete
elimination of the residual micrometastases is re-
quired. Metastases remain localized in the peritoneal
cavity throughout most of the clinical course of ovar-
ian cancer. Therefore, we consider that i.p. adminis-
tration of immuno-enzymosomes for ADEPT might
be an attractive approach for adjuvant therapy, as
the intraperitoneally localized target cells can be ex-
pected to be directly accessible for the i.p. adminis-
tered particles.
We have reported before that the introduction of
additional thiol groups was necessary for e⁄cient
coupling of the enzyme L-glucuronidase (GUS) to
the MPB-PE liposomes [9]. That led to our ‘¢rst
generation’ immuno-enzymosomes which contained
20 molecules GUS and about 400 FabP molecules
per particle. In this paper we address the following
questions: (1) To what extent is it possible to in-
crease the amount of enzyme and/or enzymatic activ-
ity associated to the immuno-enzymosomes without
occurrence of vesicle aggregation? (2) Are the cell
binding properties of immuno-enzymosomes bearing
maximal enzyme density preserved?
With regard to the ¢rst issue, an attempt was made
to increase the enzymatic activity associated to the
immuno-enzymosomes by puri¢cation of commer-
cially available GUS. As a result of the removal of
proteins other than GUS present in the commercial
preparation, the speci¢c activity of the enzyme (en-
zymatic activity per mg protein) was increased 2-fold
(Table 1). This puri¢cation step also resulted in a
2-fold increase of the amount of GUS protein
coupled to the liposomes (Table 2). The observation
that more protein was coupled to the liposomes when
puri¢ed GUS was used indicates that other non-pro-
tein components present in the commercial prepara-
tion and removed during the puri¢cation process
competed with the thiol groups of the enzyme for
the reaction with the liposome anchor molecule
(MPB-PE).
We were able to achieve a further increase in GUS
density by using a higher concentration of GUS dur-
ing the incubation with the liposomes. Immuno-en-
Fig. 6. Enzyme targeting capability of immuno-enzymosomes
with varying amounts of GUS and FabP : (S) Immuno-enzymo-
somes with high GUS density and impaired cell binding proper-
ties (GUS coupling ratio: 70 Wg GUS/Wmol TL (380 molecules
of GUS per liposome); FabP coupling ratio: 3 Wg FabP/Wmol
TL (100 molecules of FabP per liposome); GUS/FabP ra-
tio = 3.8). (b) Immuno-enzymosomes with lower GUS density
and preserved cell binding properties (GUS coupling ratio: 25
Wg GUS/Wmol TL (170 molecules of GUS per liposome); FabP
coupling ratio: 20 Wg FabP/Wmol TL (700 molecules of FabP per
liposome); GUS/FabP ratio = 0.2). Varying amounts of the lipo-
some dispersions were incubated with cells (106 cells/ml) for 90
min at 4‡C. After washing the cells with PBS containing 0.1%
BSA to remove unbound liposomes, the cell-bound enzymatic
activity was determined. A typical experiment out of three per-
formed is shown. Each point represents the mean þ S.D. of
three determinations.
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zymosomes containing up to 80 Wg GUS/Wmol TL
(700 GUS molecules per particle1) could be prepared
without occurrence of aggregation. As a matter of
fact, these immuno-enzymosomes had a 35-fold high-
er enzyme density and a 70-fold increased enzymatic
activity than our ‘¢rst-generation’ immuno-enzymo-
somes [9]. Previously, the preparation of such high
density immuno-enzymosomes was not possible due
to problems of vesicle aggregation. This improve-
ment led us to investigate the e¡ect of enzyme den-
sity on the cell binding properties of immuno-enzy-
mosomes. It is well possible that the presence of large
amounts of the bulky enzyme (280 kDa) interferes
with the interaction between FabP (50 kDa) and the
antigen expressed on the cancer cells, thus impairing
the cell binding properties of immuno-enzymosomes.
To address this problem, we ¢rst established that cell
binding of immunoliposomes was maximal at a FabP
density of approximately 15 Wg/Wmol TL (Fig. 3).
Immuno-enzymosomes with a similar FabP content
and relatively low GUS density (GUS/FabP molar
ratio of 0.2), had fully preserved cell binding proper-
ties (Fig. 5A). However, immuno-enzymosomes with
higher GUS density and/or lower FabP content
(GUS/FabP molar ratio s 0.5, see Fig. 5B, C) bound
to a much lower extent to OVCAR-3 cells than im-
munoliposomes with a similar content of FabP, thus
suggesting that, indeed, the presence of the enzyme
interferes with the binding properties of FabP-bearing
liposomes. Nevertheless, in spite of the occurrence of
GUS-mediated hindrance of target cell binding, to
achieve maximal enzyme targeting the most relevant
parameter proved to be the absolute amount of lip-
osome-associated enzymatic activity (Fig. 6). Immu-
no-enzymosomes bearing the highest enzymatic ac-
tivity showed the best enzyme targeting capability
even though their cell binding properties were nota-
bly impaired. Therefore, we conclude that increasing
the enzyme density on the surface of immuno-enzy-
mosomes, even up to levels that steric hindrance to
the interaction with the target antigen is introduced,
is an adequate strategy for developing immuno-enzy-
mosomes with maximized enzyme targeting capabil-
ity. In vivo studies addressing the applicability of
immuno-enzymosomes carrying a high enzyme den-
sity for ADEPT in an i.p. xenograft of ovarian car-
cinoma are underway.
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